小儿肺热清颗粒通过肺肠轴缓解幼鼠肺炎链球菌诱导的肺热证
该研究结合网络药理学与幼鼠体内实验,探究小儿肺热清颗粒(XEFRQ)对肺炎链球菌(STP)诱导肺热证(PPS)的作用及机制。结果显示XEFRQ可改善PPS,降低炎症因子与神经递质水平,下调与干便相关的AQP3蛋白表达,并调节肠道菌群,体现肺肠同治理念。
要点
- XEFRQ可改善STP诱导的幼鼠肺热证及肺肠病理。
- XEFRQ降低TNF-α、IL-1β、PGE2及5-HT、SP、VIP水平。
- XEFRQ下调AQP3并调节特定肠道菌群丰度。
核心结论
- XEFRQ通过影响肺与肠道缓解肺炎链球菌诱导的幼鼠肺热证。
研究设计与样本
- 采用网络药理学预测靶点,并用幼鼠体内实验验证,每组10只,设空白组、模型组及XEFRQ低剂量16.3 g/kg和高剂量56.6 g/kg组。
- PPS模型通过三轮鼻滴肺炎链球菌(0.5 mL/kg)构建,干预14天。
主要发现
- XEFRQ改善STP诱导的PPS,降低炎症因子和神经递质水平。
- XEFRQ显著降低AQP3蛋白表达,AQP3与干便相关。
- XEFRQ使[Eubacterium]_ruminantium_group、Colidextribacter、Romboutsia和Oscillibacter相对丰度降低。
关键数值与推荐
- 网络分析提示XEFRQ可能通过影响炎症因子和神经递质水平缓解PPS损伤。
临床怎么用
- 结果支持XEFRQ在儿童肺热证中的临床应用,并提示肺肠同治的潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: The traditional Chinese medicine (TCM) Xiaoer-Feire-Qing granules (XEFRQ) has been used to treat pyretic pulmonary syndrome (PPS) in children for many years. The function of the lungs is considered to be closely related to the large intestine in TCM. PURPOSE: We aimed to investigate the effects of XEFRQ on PPS and the underlying mechanisms via network pharmacology and animal experiments. METHODS: The TCMSP platform was used to identify the ingredients and potential targets of XEFRQ. The GeneCards, OMIM, and TTD databases were used to predict PPS-associated targets. Cytoscape 3.9.1 was employed to construct the protein-protein interaction network, and target prediction was performed by GO and KEGG analyses. For the animal experiment, a PPS model was constructed by three cycles of nasal drip of Streptococcus pneumoniae (STP; 0.5 mL/kg). The animals were randomly divided into the following four groups according to their weight (n = 10 rats per group): the blank group, the model group, the XEFRQ-L (16.3 g/kg) group, and the XEFRQ-H (56.6 g/kg) group. Rats in the blank group and the model group were given 0.5% CMC-Na by gavage. The general conditions of the rats were observed, and their food-intake, body weight, and body temperature were recorded for 14 days. After the intervention of 14 days, serum was collected to detect inflammatory cytokines (TNF-α, IL-1β, and PGE2) and neurotransmitters (5-HT, SP, and VIP). H&E staining was used to observe the pathological morphology of lung and colon tissue. AQP3 expression was detected by Western blot. In addition, the gut microbiota in cecal content samples were analyzed by 16S rDNA high-throughput sequencing. RESULTS: Our network analysis revealed that XEFRQ may alleviate PPS injury by affecting the levels of inflammatory cytokines and neurotransmitters and mitigating STP-induced PPS.In vivo validation experiments revealed that XEFRQ improved STP-induced PPS and reduced the expression of inflammatory cytokines and neurotransmitters. Notably, XEFRQ significantly decreased the protein expression levels of AQP3, which was associated with dry stool. Our gut microbiota analysis revealed that the relative abundance of [Eubacterium]_ruminantium_group, Colidextribacter, Romboutsia, and Oscillibacter was decreased, which means XEFRQ exerts therapeutic effects against PPS associated with these bacteria. CONCLUSION: Our results demonstrate that XEFRQ alleviates PPS by affecting the lungs and intestines, further guiding its clinical application.
引用
- Wang T, Xu X, Sun S, et al. Xiaoer-Feire-Qing granules alleviate pyretic pulmonary syndrome induced by Streptococcus pneumoniae in young rats by affecting the lungs and intestines: An in vivo study based on network pharmacology. J Ethnopharmacol. 2024. PMID: 38705426. doi:10.1016/j.jep.2024.118288
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。